sorafenib has been researched along with casein kinase ii in 2 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (casein kinase ii) | Trials (casein kinase ii) | Recent Studies (post-2010) (casein kinase ii) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 3,268 | 5 | 1,299 |
| Protein | Taxonomy | sorafenib (IC50) | casein kinase ii (IC50) |
|---|---|---|---|
| Serine/threonine-protein kinase Sgk1 | Homo sapiens (human) | 3.57 | |
| Ribosyldihydronicotinamide dehydrogenase [quinone] | Homo sapiens (human) | 0.484 | |
| Casein kinase II subunit alpha | Rattus norvegicus (Norway rat) | 0.14 | |
| Casein kinase II subunit alpha' | Homo sapiens (human) | 2.23 | |
| Cyclin-A2 | Homo sapiens (human) | 2.38 | |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | 2.38 | |
| Casein kinase II subunit beta | Homo sapiens (human) | 2.23 | |
| Casein kinase II subunit beta | Rattus norvegicus (Norway rat) | 0.14 | |
| Casein kinase II subunit alpha | Homo sapiens (human) | 2.23 | |
| Cyclin-A1 | Homo sapiens (human) | 2.38 | |
| Dual specificity tyrosine-phosphorylation-regulated kinase 1A | Homo sapiens (human) | 0.26 | |
| Casein kinase II subunit alpha 3 | Homo sapiens (human) | 0.14 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abuo-Rahma, GEA; Badr, M; Bass, AKA; El-Zoghbi, MS; Mohamed, MFA; Nageeb, EM | 1 |
| Hashemolhosseini, S; Hellerbrand, C; Klinger, N; Neureiter, D; Ocker, M; Sass, G; Sirma, H; Tiegs, G; Wege, H | 1 |
1 review(s) available for sorafenib and casein kinase ii
| Article | Year |
|---|---|
Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
Topics: Androgen Antagonists; Animals; Antineoplastic Agents; Benzimidazoles; Cyclic Nucleotide Phosphodiesterases, Type 5; Daunorubicin; Doxorubicin; fms-Like Tyrosine Kinase 3; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Molecular Targeted Therapy; Morpholines; Nicotinamide Phosphoribosyltransferase; Nitric Oxide; Pyrimidines; Quinazolines; Structure-Activity Relationship; Transcription Factors | 2021 |
1 other study(ies) available for sorafenib and casein kinase ii
| Article | Year |
|---|---|
Inhibition of experimental HCC growth in mice by use of the kinase inhibitor DMAT.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Benzimidazoles; Carcinoma, Hepatocellular; Casein Kinase II; Cell Line, Tumor; Cell Proliferation; Cell Survival; Enzyme Activation; Gene Knockdown Techniques; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice; NF-kappaB-Inducing Kinase; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pyridines; Signal Transduction; Sorafenib; Wnt Proteins; Xenograft Model Antitumor Assays | 2011 |